Osteosarcoma risk in rats using PTH 1-34

By Barbehenn E.K.   Lurie P.   Wolfe S.M.  

Trends in Endocrinology and Metabolism, Vol. 12, Iss. 9, 2001-11 ,pp. : 383-383

Elsevier

Access to resources Recommend Favorite

Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis

By Satterwhite Julie  

Calcified Tissue International, Vol. 87, Iss. 6, 2010-12 ,pp. : 485-492

Springer Publishing Company

Access to resources Recommend Favorite

Y chromosome microdeletions, sperm DNA fragmentation and sperm oxidative stress as causes of recurrent spontaneous abortion of unknown etiology

By Bellver J.   Meseguer M.   Muriel L.   Garca-Herrero S.   Barreto M.A.M.   Garda A.L.   Remoh J.   Pellicer A.   Garrido N.  

Human Reproduction, Vol. 25, Iss. 7, 2010-07 ,pp. : 1713-1721

Oxford University Press

Access to resources Recommend Favorite

Treatment with Parathyroid Hormone hPTH(1-34), hPTH(1-31), and Monocyclic hPTH(1-31) Enhances Fracture Strength and Callus Amount After Withdrawal Fracture Strength and Callus Mechanical Quality Continue to Increase

By Andreassen T. T.   Willick G. E.   Morley P.   Whitfield J. F.  

Calcified Tissue International, Vol. 74, Iss. 4, 2004-04 ,pp. : 351-356

Springer Publishing Company

Access to resources Recommend Favorite

The effect of continuous subcutaneous recombinant PTH (1–34) infusion during pregnancy on calcium homeostasis – a case report

By Ilany Jacob   Vered Iris   Cohen Ohad  

Gynecological Endocrinology, Vol. 29, Iss. 9, 2013-09 ,pp. : 807-810

Informa Healthcare

Access to resources Recommend Favorite